Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference (Q40432574)

20 September 2017

title

Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference (English)

1 reference

human papillomavirus infection

20 September 2017

main subject

1 reference

Francesca Carozzi

2

0 references

Paolo Giorgi Rossi

object named as

Paolo Giorgi Rossi

1

0 references

Silvia Franceschi

object named as

Silvia Franceschi

6

0 references

author name string

Antonio Federici

3

1 reference

20 September 2017

Guglielmo Ronco

4

1 reference

20 September 2017

Marco Zappa

5

1 reference

20 September 2017

Italian Screening in HPV vaccinated girls Consensus Conference group

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

25 November 2016

1 reference

20 September 2017

1 reference

20 September 2017

volume

98

1 reference

20 September 2017

page(s)

21-30

1 reference

Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

How to formulate research recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

HPV types in early-onset cervical cancer – Authors' reply

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus typing of invasive cervical cancers in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Knowledge, attitude and practice in primary and secondary cervical cancer prevention among young adult Italian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Long-term study of a quadrivalent human papillomavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis: association with 72-kilodalton metalloproteinase immunostaining

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Screening history of cervical cancers in Emilia-Romagna, Italy: defining priorities to improve cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus types in glandular lesions of the cervix: a meta-analysis of published studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Clinical trials of human papillomavirus vaccines and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Extralesional detection and load of human papillomavirus DNA: a possible marker of preclinical tumor spread in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Changes in cervical cancer incidence following the introduction of organized screening in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: a representative, single institution case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Untypable human papillomavirus infection and risk of cervical intraepithelial neoplasia among women with abnormal cervical cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.020

10.1016/J.YPMED.2016.11.020

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference